Skip to content


Fycompa (perampanel) is a small molecule pharmaceutical. Perampanel was first approved as Fycompa on 2012-07-23. It is used to treat partial epilepsies, seizures, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat partial epilepsies. Fycompa's patents are valid until 2026-07-01 (FDA).
Trade Name Fycompa
Common Name Perampanel
Indication partial epilepsies, seizures, tonic-clonic epilepsy
Drug Class Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors): antagonists
Get full access now